Vestal Point Capital LP purchased a new position in Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,570,000 shares of the company's stock, valued at approximately $4,729,000. Vestal Point Capital LP owned approximately 3.12% of Sutro Biopharma as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Rhumbline Advisers boosted its stake in Sutro Biopharma by 6.1% in the fourth quarter. Rhumbline Advisers now owns 126,698 shares of the company's stock valued at $233,000 after acquiring an additional 7,320 shares in the last quarter. Prudential Financial Inc. raised its stake in shares of Sutro Biopharma by 351.0% during the 4th quarter. Prudential Financial Inc. now owns 547,510 shares of the company's stock worth $1,007,000 after buying an additional 426,100 shares during the last quarter. LPL Financial LLC lifted its holdings in shares of Sutro Biopharma by 34.2% in the fourth quarter. LPL Financial LLC now owns 362,232 shares of the company's stock valued at $667,000 after purchasing an additional 92,333 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Sutro Biopharma by 15.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,136,457 shares of the company's stock worth $2,091,000 after buying an additional 156,139 shares in the last quarter. Finally, American Century Companies Inc. boosted its stake in shares of Sutro Biopharma by 29.1% during the 4th quarter. American Century Companies Inc. now owns 93,033 shares of the company's stock worth $171,000 after purchasing an additional 20,958 shares during the last quarter. 96.99% of the stock is owned by institutional investors and hedge funds.
Sutro Biopharma Stock Performance
Shares of STRO opened at $0.91 on Monday. Sutro Biopharma, Inc. has a 1 year low of $0.52 and a 1 year high of $5.17. The company has a market cap of $76.99 million, a price-to-earnings ratio of -0.57 and a beta of 1.77. The firm has a fifty day moving average of $0.80 and a 200-day moving average of $1.73.
Sutro Biopharma (NASDAQ:STRO - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.91) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.28). The company had revenue of $17.40 million for the quarter, compared to analyst estimates of $11.61 million. Sutro Biopharma had a negative net margin of 77.01% and a negative return on equity of 101.89%. Analysts predict that Sutro Biopharma, Inc. will post -2.92 EPS for the current year.
Analyst Upgrades and Downgrades
Several equities research analysts recently issued reports on the stock. Wedbush cut shares of Sutro Biopharma from an "outperform" rating to a "neutral" rating and decreased their target price for the stock from $8.00 to $2.00 in a research report on Friday, March 14th. Piper Sandler set a $2.00 price objective on shares of Sutro Biopharma in a report on Friday, March 14th. Citizens Jmp lowered shares of Sutro Biopharma from an "outperform" rating to a "market perform" rating in a research note on Friday, March 14th. Bank of America downgraded shares of Sutro Biopharma from a "buy" rating to an "underperform" rating and dropped their target price for the stock from $11.00 to $1.00 in a research report on Friday, March 14th. Finally, HC Wainwright restated a "neutral" rating and issued a $2.00 target price on shares of Sutro Biopharma in a research note on Tuesday, April 29th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $6.14.
Check Out Our Latest Research Report on STRO
Sutro Biopharma Company Profile
(
Free Report)
Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.
Featured Articles
Want to see what other hedge funds are holding STRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sutro Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sutro Biopharma wasn't on the list.
While Sutro Biopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
